<DOC>
	<DOCNO>NCT02822014</DOCNO>
	<brief_summary>Objective Prospectively describe kinetics 18F-FDG uptake extrapulmonary TB two month end TB treatment HIV patient . Evaluate 18F-FDG-PET/CT TB treatment response monitoring tool . Design The investigator perform baseline FDG-PET/CT , another FDG-PET/CT 2 month TB treatment PET/CT end treatment 18 HIV/TB patient . The investigator correlate evolution FDG uptake clinical evolution patient .</brief_summary>
	<brief_title>PET/CT Extrapulmonary TB HIV Patients : Clinical Trial</brief_title>
	<detailed_description>Materials Methods Eighteen HIV-positive patient , 18 year old , extra pulmonary TB enrol provide write informed consent . Baseline FDG-PET/CT perform soon possible initiate TB treatment , follow FDG-PET/CT 2 month TB treatment end TB treatment accord guideline ( 6 months/9-12 month bone CNS TB ) . However , real duration treatment leave discretion physician , blind result second third FDG-PET/CT . Patients Collected data : demographic , mode HIV infection , nadir CD4 cell count , history/date cART start , mode/date TB diagnosis , HIV immunovirological status time TB diagnosis , date TB treatment , culture DST ( Drug Susceptibility Test ) result M. tuberculosis , histopathology result , IRIS ( immune reconstitution inflammatory syndrome , document treat physician ) , corticosteroids administration TB relapse follow-up least 36 month end TB treatment . TB classify proven culture , molecular biology ( PCR ) positive M. tuberculosis/ histopathology show caseous granulomatosis , probable patient improve TB treatment without diagnosis additional criterium ( i.e . CSF analysis compatible TB meningitis , biopsy show granuloma ) . Clinical biological follow perform every 4 month least 36 month . FDG-PET/CT analysis Two experience nuclear medicine physician , blind clinical , bacteriological histopathological finding , interpret FDG-PET/CT image . They follow predefined reading frame , look first 9 lymph node site ( cervical , axillary , mediastinal , hilar , retroperitoneal , portal-hepatic , mesenteric , iliac , inguinal ) FDG uptake include organ . A site designate abnormal FDG activity increase relative adjacent normal soft-tissue . The number abnormal site ( lymph node site organ ) count . Qualitative assessment make Visual score site : score 1 define less 5 visible active lymph node , score 2 5 10 visible active lymph node score 3 much lymph node count , massive confluence lymph node site . The 3 great lymph node sit per patient term visual score describe detail analysis . FDG-PET quantitatively analyze use SUVmax . SUVmax correspond maximum Standardized Uptake Value ( SUV ) voxel within circular region interest drawn manually site show FDG uptake . SUVmax measure active lymph node lymph node site . Concerning organ FDG uptake , SUVmax active organ describe . Percentage change SUVmax serial FDG-PET/CT ( DeltaSUVmax ) calculate follow : % DSUVmax = ( SUVmaxT0 - SUVmaxT2 ) / SUVmaxT0 x 100 ( T0 baseline FDG-PET/CT T2 either PET2 PET3 ) . DeltaSUVmax consider significant â‰¥ 20 % . In analysis , PET2 perform 2 month TB treatment compare baseline FDG-PET/CT ( PET1 ) . PET3 , perform end TB treatment , compare PET1 .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>HIVinfected patient age least 18 year old high clinical suspicion extrapulmonary tuberculosis predominant neurological symptom pregnancy positive smear sputum tuberculosis MDR XDR tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>